Related Experiment Video
Updated: Feb 14, 2026

Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
ATP Synthase, a Target for Dementia and Aging?
James W Larrick1,2, Jasmine W Larrick1, Andrew R Mendelsohn1,2
11 Panorama Research Institute , Sunnyvale, California.
Abstract:
Advancing age is the biggest risk factor for development for the major life-threatening diseases in industrialized nations accounting for >90% of deaths. Alzheimer's dementia (AD) is among the most devastating. Currently approved therapies fail to slow progression of the disease, providing only modest improvements in memory. Recently reported work describes mechanistic studies of J147, a promising therapeutic molecule previously shown to rescue the severe cognitive deficits exhibited by aged, transgenic AD mice. Apparently, J147 targets the mitochondrial alpha-F1-ATP synthase (ATP5A). Modest inhibition of the ATP synthase modulates intracellular calcium to activate AMP-activated protein kinase to inhibit mammalian target of rapamycin, a known mechanism of lifespan extension from worms to mammals.
Insights
Aging increases the risk of fatal diseases like Alzheimer's dementia (AD). J147, a therapeutic molecule, targets mitochondrial ATP synthase, potentially offering a new avenue for AD treatment and lifespan extension.
Area of Science:
- Gerontology and Neurodegenerative Diseases
- Mitochondrial Biology
- Drug Discovery
Background:
- Advancing age is the primary risk factor for major life-threatening diseases, including Alzheimer's dementia (AD).
- Current AD therapies offer limited efficacy, primarily symptomatic relief without halting disease progression.
- J147 is a therapeutic molecule demonstrating efficacy in rescuing cognitive deficits in aged AD mouse models.
Purpose of the Study:
- To elucidate the mechanism of action for J147, a promising therapeutic candidate for Alzheimer's dementia.
- To investigate the molecular targets and pathways modulated by J147 in the context of aging and cognitive decline.
Main Methods:
- Mechanistic studies were performed to identify the molecular target of J147.
- Investigated the effects of J147 on mitochondrial alpha-F1-ATP synthase (ATP5A) activity.
- Assessed the downstream signaling pathways, including intracellular calcium modulation, AMP-activated protein kinase (AMPK), and mammalian target of rapamycin (mTOR) signaling.
Main Results:
- J147 was identified to target the mitochondrial alpha-F1-ATP synthase (ATP5A).
- Modest inhibition of ATP synthase by J147 modulates intracellular calcium levels.
- This modulation activates AMP-activated protein kinase (AMPK), leading to the inhibition of mammalian target of rapamycin (mTOR).
Conclusions:
- J147's mechanism involves the modulation of mitochondrial ATP synthase, impacting key cellular signaling pathways.
- The identified pathway (ATP synthase inhibition -> calcium modulation -> AMPK activation -> mTOR inhibition) is a known mechanism for lifespan extension.
- These findings suggest J147 as a potential therapeutic agent for Alzheimer's dementia and possibly for promoting longevity.
Related Concept Videos
ATP Synthase: Structure
ATP Synthase: Mechanism
Dementia
The progression of dementia is generally gradual....
ATP Yield
The ETC is embedded in the inner mitochondrial membrane and is comprised of four main protein complexes and an ATP synthase. NADH and FADH2 pass electrons to these complexes, which pump protons into the intermembrane space. This distribution of...
Hydrolysis of ATP
If one phosphate group is removed, a molecule of ADP—adenosine diphosphate—remains, along with inorganic phosphate. ADP can be further hydrolyzed to AMP—adenosine...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

